Start the conversation
I believe this will be the "Summer of the Small-Cap Stocks."
Before I explain why this will be so, let's take a look at why small-cap firms - public companies with market capitalizations of $300 million to $2 billion - are so important to tech investors.
Obviously the most attractive aspect of a small-cap stock is its potential to show massive returns. One reason is that small-cap firms can grow quickly. After all, a $350 million biotech can double in size in a few years. A $20 billion company cannot.
In January, Barron's reported on a study showing that small-cap stocks do indeed outperform larger ones - if you select "quality" stocks. Quality is measured by looking at things like profit growth and earnings stability.
This study basically reaffirmed a principle that investors have long known: There is a decided "small firm effect" or "size premium" that allows small-cap stocks to consistently beat larger ones.
Consider that, over the past decade, the closely watched Russell 2000 Index of small caps has beaten the S&P 500 by roughly 26%.
While small caps' performance this year has roughly matched that of the overall market, small-cap gains in the last eight months have outpaced the overall market.
Here's why. A year ago this week, Wall Street became convinced that the U.S. economy was on the verge of significantly slowing down.
As a result, from July 2 to Oct. 14, 2014, the Russell 2000 fell more than 11%. That was more than double the S&P 500's decline over the same period.
But Wall Street is once again waking up to the fact that the U.S. economy and small-cap stocks are great places to make money. That the Russell 2000 made up all that ground in the last eight months to come even with the S&P clearly demonstrates that fact.
Just last week, the U.S. Department of Commerce revised its growth estimates for this year's first quarter upward by 71%. The DOC had originally said gross domestic product (GDP) fell by 0.7% in the quarter, but the decline was actually just 0.2%.
The news came on the heels of strong job growth. In early June, the U.S. Department of Labor said the economy added some 285,000 nonfarm jobs in May, the last month for full data.
It was the highest job growth since December and means that the economy has added more than 1 million jobs so far this year.
Meanwhile, the bellwether housing sector also is reporting robust growth. On Monday, the National Association of Realtors said its index of pending home sales increased 0.9% to a seasonally adjusted 112.6 - the highest level since April 2006.
And there's one more factor that bodes well for the Summer of the Small-Cap Stocks...
A Perfect Ratio
As a group, these smaller firms are priced to move. You can see that in the forward price-to-earnings (P/E) ratio. I use this ratio all the time because it tells me how much I'm paying for next year's earnings.
But the Russell 2000 has a forward P/E ratio of just 19.25. In other words, you can buy a basket of small, hyper-growth companies for less than their mega-cap counterparts.
That's why I think every tech investor ought to own the iShares Russell 2000 Growth ETF (NYSE: IWO). As the name implies, this exchange-traded fund seeks to mirror the performance of the Russell 2000 - and it's selected those "quality" stocks I mentioned earlier.
This is a "twofer" investment. It gives us exposure to not only fast-moving tech small caps, but also small companies in other growth sectors.
Information technology and healthcare, which includes biotech and medical equipment, make up 51% of the fund. Other industries represented include heavy industry, financial services, and consumer discretionary.
But make no mistake. Exciting tech leaders form the core of the IWO.
Two "Million Dollar" Winning Small-Cap Stocks
The first is video-processing chip firm Ambarella Inc. (Nasdaq: AMBA). Over the past three years, Ambarella has grown its sales by 32% and its earnings by 52%.
By comparison, Cisco has grown its sales by just 1% and its earnings per share by 6% over the same period.
More pertinent to us, as investors, is that Ambarella's share price has soared 212.21% over the past year, while Cisco's has inched up 8.06%.
IWO's other Million Dollar Tech Portfolio holding is biotech supply firm Repligen Corp. (Nasdaq: RGEN). Over the past three years, it has grown sales by 16% and earnings per share by 45%.
Then there's Qorvo Inc. (Nasdaq: QRVO). It's known as a supplier of radio-frequency chips used in defense, cable TV systems, tablets, and smartphones.
Qorvo boasts an impressive list of marquee clients - including The Boeing Co. (NYSE: BA), Raytheon Co. (NYSE: RTN), and Sony Corp. (NYSE: SNE). Qorvo has 15% operating margins and sales by 148% in the most recent quarter.
IWO also owns specialty e-commerce firm Blackbaud Inc. (Nasdaq: BLKB), which caters to nonprofits such as research foundations and universities.
Blackbaud has some 29,000 clients that rely on the firm for help in managing their fundraising, accounting, online marketing, and payment services. With a market cap of $2.6 billion, Blackbaud has a 16% return on equity and recently grew its quarterly earnings by some 16%.
Aspen Technology Inc. (Nasdaq: AZPN), the fund's 10th-largest holding, is another high-margin firm in the IWO portfolio. The software company's products help manufacturers cut costs, improve supply-chain efficiency, and increase profit margins. Aspen has an astounding return on equity of 384% and grew its most recent quarterly earnings by 35%.
[epom key="ddec3ef33420ef7c9964a4695c349764" redirect="" sourceid="" imported="false"]
Not only does IWO provide investors access to more than 1,200 stocks in a single ETF, it also offers market-beating performance.
After the market's big sell-off on June 29, the S&P was at breakeven for the year. But IWO's return for the period came in at 8%.
I'm calling this a comeback.
However, it remains true that small caps can be riskier than their large-cap cousins.
But with the IWO doing the "picking" for you, it's the kind of foundational technology play that you can count on over the long haul to keep you on the road to wealth.
Pay No Attention to the Little Tech Company, Apple Inc., Over There... With Apple so often on the cutting edge of technology, it is easy to treat its latest breakthroughs as the status quo for such an innovator. But the newest big story out of Cupertino is hardly the status quo - even for a firm like Apple Inc. Here's how the tech giant is about to upend a mature market...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.